PARD (Poniard Pharmaceuticals) Buyback Yield %: 0.00 (As of Jun. 30, 2026)


What is Poniard Pharmaceuticals Buyback Yield %?

Poniard Pharmaceuticals PARD Buyback Yield % is 0.00 as of Jun. 30, 2026.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Poniard Pharmaceuticals's current buyback yield was 0.00%.

Poniard Pharmaceuticals Buyback Yield % Related Terms

Poniard Pharmaceuticals Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Buyback Yield % Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -51.32 -45.75 0.00 -17.82 -24.13

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PARD vs OBMP, NSPX, ATRX: Buyback Yield % Comparison

For the Biotechnology subindustry, Poniard Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poniard Pharmaceuticals Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's Buyback Yield % falls into.


Poniard Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Poniard Pharmaceuticals's Buyback Yield for the fiscal year that ended in Dec. 2010 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 6.092) / 25.2512
=-24.13%

Poniard Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Sep. 2011 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 3.184) / 7.495
=-42.48%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Poniard Pharmaceuticals (PARD) has a Buyback Yield % of 0.00 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' Buyback Yield % too high?
Poniard Pharmaceuticals' current Buyback Yield % is 0.00.
How does Poniard Pharmaceuticals' Buyback Yield % compare to OBMP and NSPX?
Poniard Pharmaceuticals' Buyback Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Buyback Yield % is 0.00 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.